SOPURA acquired by KERSIA

Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially. The primary goal was to provide Banook with the resources to accelerate its buy-and-build strategy, focusing on North American expansion and diversification into eCOA and biostatistics.

Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets. The deal structure allowed the founder, Miroslav Reljanović, to roll over a portion of his equity and remain involved, ensuring continuity. Strategically, Permira aims to supercharge Ergomed's "Site Management" model and its pharmacovigilance capabilities through both organic investment and accretive M&A.

Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs. The transaction followed Cerba's previous major international acquisitions of Lifebrain (Italy) and Viroclinics-DDL (Netherlands), furthering the global expansion strategy initiated under EQT's majority ownership since 2021.

Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs. A significant portion of the capital is earmarked for strengthening commercial and technical teams in Europe and the United States, as well as deepening strategic partnerships with global medical imaging equipment manufacturers (OEMs).

Astorg has successfully completed the acquisition of OPEN Health from Amulet Capital Partners, executing a significant secondary buyout in the highly attractive healthcare services sector. Through this transaction, Astorg secures a controlling interest in a premier medical affairs and market access business, while the existing management team will continue to helm the organization. The strategic rationale for Astorg is deeply rooted in acquiring a highly scalable platform investment within the rapidly professionalizing medical communications space. As the pharmaceutical industry shifts toward complex, next-generation therapeutics, the demand for specialized, high-science communication and rigorous data analytics has transformed medical affairs from a supportive function into a central commercial driver. Astorg intends to deploy its substantial dry powder and leverage its extensive healthcare expertise to accelerate the company's next phase of growth, supporting both organic initiatives and highly targeted, value-accretive strategic acquisitions.

IK Investment Partners acquired a majority stake in Kersia from Ardian. This transaction was initiated through exclusive negotiations via the IK IX fund, marking the first deal for this specific vehicle. The investment strategy is focused on supporting the group through its next phase of growth and continuing an active global sector consolidation policy. The project builds on the target's remarkable trajectory, having tripled in size in less than four years through the successive integration of six specialized companies. The new shareholder intends to capitalize on the group's technological expertise and extensive geographical presence to reinforce its leadership in the food safety sector. The transaction also allows the historical shareholder to realize the value created while passing the baton to a partner experienced in supporting high-growth industrial leaders.

Clayton, Dubilier & Rice, LLC completed its acquisition of Huntsworth PLC on May 1, 2020. The strategic rationale centers on Huntsworth’s position as a leading pharma commercialization services platform, with a strong Health division contributing roughly 85% of the group’s operating profit. CD&R views the company’s underlying markets as attractive, underpinned by long‑term healthcare trends such as demographic shifts, rising drug innovation, increasing outsourcing of commercial and medical services, and the growing complexity of marketing and access channels for specialized therapies. The investment aligns with CD&R’s healthcare‑focused strategy and experience with similar hybrid healthcare‑services models, including its prior involvement with platforms comparable to Huntsworth through former executives such as Liam FitzGerald, an operating advisor who assumed the role of Chairman. From a value‑creation standpoint, the transaction allows Huntsworth to pursue accelerated organic growth and targeted acquisitions without the constraints of public‑market volatility, while CD&R aims to strengthen operational discipline, deepen sector penetration, and broaden the group’s service offerings.

Spectris plc has successfully finalized the acquisition of 100% of the share capital of the target from a mid-market private equity firm. This strategic transaction represents a definitive step in the group’s evolution toward a combined product-and-service proposition within its specialized materials analysis segment. The strategic rationale for the move centers on the high degree of complementarity between the target’s scientific service capabilities and the acquirer’s established instrumentation expertise, particularly through its existing subsidiary, Malvern Panalytical. By incorporating this technical specialist, the organization reinforces its ability to serve mission-critical pharmaceutical and agrochemical markets facing increased regulatory complexity. The partnership is designed to leverage the acquirer’s global reach and deep domain knowledge to accelerate innovation in molecular testing and therapy development. This integration facilitates a unique end-to-end offering, providing the strategic depth required to navigate the sophisticated requirements of protein-based pharmaceutical research. The move marks a significant expansion into high-growth life sciences services, positioning the combined entity as a primary enabler of advanced drug discovery workflows.

Charles River Laboratories has finalized the acquisition of WIL Research from a shareholder group led by American Capital, Ltd. and The Wicks Group. The strategic rationale for this transaction centers on a "service-continuum" play, merging the target's technical operational depth in specialty safety assessment and CDMO services with the group's established global contract research infrastructure. This fusion effectively creates a specialized powerhouse in the early-stage CRO market, providing the organization with the scientific talent required to manage complex R&D requirements for pharmaceutical and industrial chemical clients. This operation allows Charles River Laboratories to enhance its competitive positioning by adding niche toxicological expertise that is critical for regulatory validation. By integrating the target’s specialized technical assets, the group can now provide a more robust and integrated solution set for high-stakes safety assessment, facilitating faster and more certain decision-making for its global customer base. The maneuver optimizes the group's financial profile by adding high-margin, specialized revenue streams from non-discretionary research sectors. Ultimately, the partnership solidifies the organization’s standing as a primary enabler of biopharmaceutical innovation, while ensuring the group remains a highly focused and agile market leader in the drug development lifecycle.

Clinigen Group acquired IDIS from private equity firm CBPE Capital. This acquisition brings together the two leading players in the ethical unlicensed medicines market. For CBPE, this exit represents a phenomenal success story: after backing the management buyout in 2005 and holding the asset for a decade, they achieved a 22x return on their original investment. The industrial logic for Clinigen is to consolidate the fragmented $5 billion unlicensed medicines market, combining IDIS's regulatory expertise and broad geographic footprint with Clinigen's existing infrastructure to serve healthcare professionals and pharma clients more effectively worldwide.